LDS/Medical Tests/4q25 Atrial Fibrillation Risk Genotype Test

4q25 Atrial Fibrillation Risk Genotype Test

Atrial Fibrillation (AF) is one of the most common cardiac arrhythmias. The US incidence was estimated at 1.2 million cases in 2010 but recent studies have shown that this is increasing and predict an incidence of 2.5 million cases by 2030. The risk of developing AF doubles with each decade of life. The underlying etiology of AF has been an interesting field of study for researchers. Previously, it was believed that only lifestyle factors affected the risk of developing AF. However, studies have shown that genetic predisposition should also be taken into account when it comes to AF risk evaluation and treatment. Gene-mediated AF tends to be more severe and unresponsive to anti-arrhythmic drugs and catheter-based electrical ablation treatment. Several genetic markers associated with an increased risk of AF have been identified.

Two Single Nucleotide Polymorphisms (SNPs) on the long arm of chromosome 4 at position 25 (4q25), rs2200733 and rs10033464, are associated with increased AF risk that has reduced response to therapy. Nearly 75% of the patients with AF are positive for either or both of the two SNPs. However, as these SNPs are present in approximately 20% of the population there must be additional factor(s) responsible for the onset of AF in individuals harboring one or both of these SNPs. A possible mechanism may be alteration in the function of the PITX2 gene secondary to these polymorphisms. PITX2 is adjacent to the 4q25 locus and is responsible for cardiac development, development of pulmonary veins, and left to right symmetry. It is postulated that polymorphisms in 4q25 result in genetic modifications of PITX2 effecting the expression of cardiac ion channels, which may alter sinus node potential and ultimately result in AF. There are unique risk genotypes for each of the two polymorphisms which are described in the interpretation section below. Testing in patients with a familial history of AF can identify individuals at risk and simultaneously, provide information for risk assessment and treatment of AF if it develops.

  • Confirms genetic predisposition for atrial fibrillation
  • As aid in diagnosis of atrial fibrillation
  • Aids in screening individuals with a familial history of atrial fibrillation
  • Therapy selection and disease management

A positive result indicates the presence of polymorphisms in the 4q25 allele and predisposition of atrial fibrillation and stroke.

Risk assessment based on genotypes:

Normal risk of atrial fibrillation (AF) and stroke

rs2200733

  • Genotype C/C

Normal risk of atrial fibrillation (AF) and stroke

rs10033464

  • Genotype G/G

 

1.5-fold increased risk of atrial fibrillation (AF) and stroke

  • Genotype T/C
  • Genotype T/T

1.4-fold increased risk of atrial fibrillation (AF) and stroke

  • Genotype T/G
  • Genotype T/T
SNP Classification Genotype
rs2200733 Optimal Genotype C/C
Borderline Genotype T/C
Genotype T/T
rs10033464 Optimal Genotype G/G
Borderline Genotype T/G
Genotype T/T
Real-time Polymerase Chain Reaction (PCR), Sanger sequencing. (Specific probes for single nucleotide polymorphisms can be utilized).

Whole Blood, Lavender-top (EDTA), buccal swab.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days (preferred)
  • Frozen: 30 days
Haptoglobin genotype test, KIF6 statin benefit genotype test, 9p21 CVD risk genotype test, PITX2 gene mutation analysis, CK-MB, myoglobin, NT-proBNP, troponin T/I.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login